- Home
- FBIO vs OTLK Comparison
FBIO vs OTLK Comparison
Compare FBIO & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBIO
- OTLK
- Stock Information
- Founded
- FBIO 2006
- OTLK 2010
- Country
- FBIO United States
- OTLK United States
- Employees
- FBIO N/A
- OTLK N/A
- Industry
- FBIO Biotechnology: Pharmaceutical Preparations
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FBIO Health Care
- OTLK Health Care
- Exchange
- FBIO Nasdaq
- OTLK Nasdaq
- Market Cap
- FBIO 49.1M
- OTLK 48.3M
- IPO Year
- FBIO N/A
- OTLK 2016
- Fundamental
- Price
- FBIO $1.89
- OTLK $1.84
- Analyst Decision
- FBIO Strong Buy
- OTLK Strong Buy
- Analyst Count
- FBIO 3
- OTLK 5
- Target Price
- FBIO $21.00
- OTLK $10.20
- AVG Volume (30 Days)
- FBIO 178.7K
- OTLK 696.2K
- Earning Date
- FBIO 05-15-2025
- OTLK 05-15-2025
- Dividend Yield
- FBIO N/A
- OTLK N/A
- EPS Growth
- FBIO N/A
- OTLK N/A
- EPS
- FBIO N/A
- OTLK 0.83
- Revenue
- FBIO $57,784,000.00
- OTLK N/A
- Revenue This Year
- FBIO $63.20
- OTLK N/A
- Revenue Next Year
- FBIO $66.70
- OTLK $288.46
- P/E Ratio
- FBIO N/A
- OTLK $2.22
- Revenue Growth
- FBIO N/A
- OTLK N/A
- 52 Week Low
- FBIO $1.33
- OTLK $0.87
- 52 Week High
- FBIO $2.89
- OTLK $9.25
- Technical
- Relative Strength Index (RSI)
- FBIO 60.90
- OTLK 57.34
- Support Level
- FBIO $1.66
- OTLK $1.55
- Resistance Level
- FBIO $1.96
- OTLK $1.90
- Average True Range (ATR)
- FBIO 0.11
- OTLK 0.18
- MACD
- FBIO 0.01
- OTLK 0.01
- Stochastic Oscillator
- FBIO 80.56
- OTLK 52.21
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.